You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 3,974,269

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 3,974,269

Title:	Radioimmune assay method for detection of gonorrhea antibodies
Abstract:	Gonorrhea antibodies in serum are detected by determination of radioactivity of conjugate formed between antibodies and antigens labelled with radioactive isotope.
Inventor(s):	Maley; Frank (Delmar, NY)
Assignee:	Research Corporation (New York, NY)
Application Number:	05/487,971
Patent Claims:	1. A radioimmunoassay method for determining the presence of Neisserria gonorrhoeae antibodies in human serum which comprises the steps of: A. adding anti-human IgG to the serum to be tested in a buffered aqueous medium, B. thereafter adding a heat labile antigen which has been produced by a growth culture of Neisseria gonorrhoeae, isolated therefrom, and labelled with a detectable radioactive element, C. incubating resulting mixture at from about 4.degree.C to 45.degree.C for from about 24 to 2 hours at a pH of from about 6.5 to 8.5 to form an antigen-antibody conjugate when said antibodies are present, and D. determining the level of radioactivity as a measure of the presence of said antigen-antibody conjugate. 2. A method as in claim 1 wherein the radioactive element is .sup.125 I. 3. A radioimmunoassay method for determining the presence of Niesseria gonorrhoeae antibodies in human serum which comprises the steps of: A. adding anti-human IgG to the serum to be tested in a buffered aqueous medium, B. thereafter adding a heat labile antigen which has been produced by a growth culture of Neisseria gonorrhoeae, isolated therefrom, and labelled with a detectable radioactive element, C. incubating resulting mixture at from about 4.degree.C to 45.degree.C for from about 24 to 2 hours at a pH of from about 6.5 to 8.5 to form an antigen-antibody conjugate when said antibodies are present, D. filter resulting mixture through a filter which has been previously washed with a reagent selected from the group consisting of bovine serum albumin, human serum immunoglobulin, ovalbumin, and hemoglobin to separate said antigen-antibody conjugate, and E. determining the level of radioactivity in resulting precipitate as a measure of the presence of said antigen-antibody conjugate. 4. A method as in claim 3 wherein the radioactive element is .sup.125 I. 5. A method as in claim 3 wherein the reagent utilized in Step D is bovine serum albumin. 6. A method as in claim 3 wherein the radioactive element is .sup.125 I and the reagent utilized in Step D is bovine serum albumin. 7. A radioimmunoassay method for determining the presence of Neisseria gonorrhoeae antibodies in human serum which comprises the steps of: A. adding anti-human IgG to the serum to be tested in a buffered aqueous medium containing a reagent selected from the group consisting of bovine serum albumin, human serum immunoglobulin, ovalbumin, and hemoglobin, B. thereafter adding a heat labile antigen which has been produced by a growth culture of Neisseria gonorrhoeae, isolated therefrom, and labelled with a detectable radioactive element together with bovine serum albumin, C. incubating resulting mixture at from about 4.degree.C to 45.degree.C for from about 24 to 2 hours at a pH of from about 6.5 to 8.5 to form an antigen-antibody conjugate when said antibodies are present, D. diluting resulting mixture with an aqueous buffer and centrifuging, and E. determining the level of radioactivity in resulting precipitate as a measure of the presence of said antigen-antibody conjugate. 8. A method as in claim 7 wherein the reagent is bovine serum albumin. 9. A method as in claim 7 wherein the radioactive element is .sup.125 I. 10. A method as in claim 7 wherein the buffer is phosphate buffered saline. 11. A method as in claim 7 wherein the reagent is bovine serum albumin, the radioactive element is .sup.125 I and the buffer is phosphate buffered saline.

Details for Patent 3,974,269

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2040-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.